Caribou Biosciences (CRBU) investor relations material

Pipeline and clinical data updates

• Additional follow-up data for vispa-cel and CB-011 expected in 2026, with dose expansion for CB-011 initiated and updates planned for the same year.

• Pivotal trial for vispa-cel in second-line large B-cell lymphoma being finalized with the FDA, targeting about 250 patients and a PFS endpoint.

• CB-011 has robust initial data from 48 patients, with expansion cohort underway and regulatory discussions planned.

• vispa-cel holds RMAT designation, enabling frequent and productive FDA interactions.

Financing and partnership strategy

• Funding for the pivotal trial will combine equity, business development, and non-dilutive sources, with full funding required through data readout.

• Business development is considered for funding but not the base case due to timing; partnerships may involve companies already in cell therapy or those seeking lower cost of goods.

• vispa-cel's cost of goods is anticipated to be 96% lower than autologous CAR T therapies, making it attractive for new entrants.

Market access and operational planning

• Off-the-shelf allo CAR T enables immediate treatment, addressing unmet needs for patients unable to access or wait for autologous CAR T.

• Demand exists at both academic and sophisticated community centers, with readiness to adopt allogeneic CAR T as infrastructure and experience grow.

• For the pivotal trial, 10 donor lots will supply enough doses for 250 patients, with scalability for broader U.S. and global launches.

• Manufacturing is commercially ready, with a single 500 sq ft suite able to produce 9,000 doses annually.